


Appl. No. 10/632,187
 Amdt. Dated May 3, 2005
 Reply to Non-Final Office Action of November 3, 2004
 Page 2 of 13


This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claim 1 (amended): The method of using of alkylphosphocholines of the general Formula I and ~~II~~ II:



Formula I



Formula II

in which, independently of one another,

n, m, p, z is a whole number between 0 and 4;

x is O, S, NH;


R is hydrogen, a linear or branched C₁ to C₂₀ alkyl group, which may be saturated or unsaturated with one to three double and/or triple bonds and unsubstituted or optionally substituted at the same or at different carbon atoms with one, two or more halogen, nitro, cyano, hydroxy, ~~C~~₁ to C₆ alkoxy, amino, mono-(~~C~~₁ to C₄) alkylamino or di-(C₁ to C₄) alkylamino groups;

R₁, R₂, R₃ independently of one another represent hydrogen, a linear or branched (~~C~~₁ to C₆) alkyl group, preferably methyl and ethyl, a ~~(C₃ to C₆) cycloalkyl group (C₁ to C₇)~~ cycloalkyl group, which may be unsubstituted or optionally substituted at the s: me

Appl. No. 10/632,187
 Amdt. Dated May 3, 2005
 Reply to Non-Final Office Action of November 3, 2004
 Page 3 of 13

or different carbon atoms with one, two or more halogen, nitro, cyano, hydroxy, C_1 to C_6 alkoxy, amino, mono- $(C_1$ to $C_4)$ alkylamino or di- $(C_1$ to $C_4)$ alkylamino groups and pharmaceutically acceptable salts and prodrugs thereof; for the manufacture of a drug product for the treatment of benign and malignant oncogenes before and/or during treatment with an approved ~~antitumor medicament~~ antitumor ~~or substance chosen from cis-platinum, carboplatinum, oxaliplatinum, bleomycin, doxorubicin, methotrexate, paclitaxel, docetaxel, vincristine, vinblastine, etoposide, teniposide, ifosfamide, cyclophosphamide, 5-fluorouracil, fludarabin, gemcitabine and cytarabin~~ and pharmaceutically acceptable salts and prodrugs thereof.

Claim 2 (amended): The method of using of compound having the structure of Formula I:



Formula I

where, independently of one another,

n is the integer 1 or 2;

m is the integer 1;

x is O;

R is H or a straight-chain or branched (C_1-C_{17}) -alkyl group which may be saturated or unsaturated with one to three double and/or triple bonds;

R_1 , R_2 , R_3 are, independently of one another, H or a straight-chain or branched (C_1-C_4) -alkyl group, preferably methyl and ethyl, a (C_3-C_7) -cycloalkyl group;

Appl. No. 10/632,187


Amdt. Dated May 3, 2005

Reply to Non-Final Office Action of November 3, 2004

Page 4 of 13

for the manufacture of a drug product for the treatment of benign and malignant oncos :s
before and/or during treatment with an approved ~~antitumor medicament~~ antitumor ~~or~~
substance chosen from cis-platinum, carboplatinum, oxaliplatinum, bleomycin,
doxorubicin, methotrexate, paclitaxel, docetaxel, vincristine, vinblastine, etopo side,
teniposide, ifosfamide, cyclophosphamide, 5-fluorouracil, fludarabin, gemcitab in
and cytarabin.

Claim 3 (amended): The method of using of alkylphosphocholines of the general Formula II as
claimed in claim 1



Formula II

where, independently of one another,

m, p are the integer 1;

n, z are the integer 2;

x is O;

R is H or a straight-chain or branched (C₁-C₁₇)-alkyl group which may be saturated or
unsaturated with one to three double and/or triple bonds;

R₁, R₂, R₃ are, independently of one another, H or a straight-chain or branched (C₁-C₄)alkyl
group, preferably methyl and ethyl, a (C₃-C₇)-cycloalkyl group;

Appl. No. 10/632,187
Amdt. Dated May 3, 2005
Reply to Non-Final Office Action of November 3, 2004
Page 5 of 13

for the manufacture of a drug product for the treatment of benign and malignant oncose s
before and/or during treatment with an approved antitumor medicament antitum or
substance chosen from cis-platinum, carboplatinum, oxaliplatinum, bleomycin,
doxorubicin, methotrexate, paclitaxel, docetaxel, vincristine, vinblastine, etopo: ide,
teniposide, ifosfamide, cyclophosphamide, 5-fluorouracil, fludarabin, gemcitab n
and cytarabin.

Claim 4 (amended): The method of using ef octadecyl 1,1-dimethylpiperidinium-4-yl phosphate as
claimed in claim 1 for the manufacture of a drug product for the treatment of benign and
malignant oncose s before and/or during treatment with an approved antitumor medicament
antitumor substance chosen from cis-platinum, carboplatinum, oxaliplatinum, bleomycin,
doxorubicin, methotrexate, paclitaxel, docetaxel, vincristine, vinblastine, etoposide, tenipo: ide,
ifosfamide, cyclophosphamide, 5-fluorouracil, fludarabin, gemcitabin and cytarabin.

Claim 5 (amended): The method of using ef alkylphosphocholines of the general formula Formu a I
and or II as claimed in elaims 1 to 4, where as in any one of the preceding claims, in which the
approved antitumor medicaments may be alkylating agents, antimetabolites, plant alkaloids,
platinum compounds, tumor antibiotics and agonists or antagonists of natural hormones.

Claim 6 (original): The method of using as claimed in claim 5, wherein the antitumor medicam: nts
may be cisplatin, cyclophosphamide or Adriamycin.

Claim 7 (amended): The method of using ef alkylphosphocholines of the general Formula I and r II
as claimed in elaims 1 to 4, where as in any one of claims 1, 2, 3, and 4, in which the appro ed

Appl. No. 10/632,187
Amtd. Dated May 3, 2005
Reply to Non-Final Office Action of November 3, 2004
Page 6 of 13

antitumor medicaments may be inhibitors of signal transduction in the form of high and low molecular weight inhibitors of receptor and/or cytosolic kinases.

Claim 8 (original): The method of using as claimed in claim 7, where the inhibitors may be monoclonal antibodies or heterocyclic compounds.

Claim 9 (amended): The method of using of alkylphosphocholines of the general Formula I and or II as claimed in ~~claims 1 to 8~~ any one of the preceding claims in a therapeutic dose which is effective for the treatment before and/or during the treatment with an approved antitumor medicament antitumor substance chosen from cis-platinum, carboplatinum, oxaliplatinum, bleomycin, doxorubicin, methotrexate, paclitaxel, docetaxel, vincristine, vinblastine, etoposide, teniposide, ifosfamide, cyclophosphamide, 5-fluorouracil, fludarabin, gemcitabin and cytarabin.

Claim 10 (amended): The method of using of alkylphosphocholines of the general formula ~~Formula I~~ Formula I and or II as claimed in ~~claims 1 to 9~~ any one of the preceding claims, where the approved antitumor medicament is a combination of various cytostatics.

Claim 11 (amended): The method of using of alkylphosphocholines of the ~~formula~~ Formula I and or II as claimed in ~~claims 1 to 4~~ any one of claims 1, 2, 3, and 4 for the manufacture of a drug product for the treatment of benign and malignant oncoses before and/or during the treatment with an approved ~~antitumor medicament~~ antitumor substance chosen from cis-platinum, carboplatinum, oxaliplatinum, bleomycin, doxorubicin, methotrexate, paclitaxel, docetaxel, vincristine, vinblastine, etoposide, teniposide, ifosfamide, cyclophosphamide, 5-fluorouracil,

Appl. No. 10/632,187
Amdt. Dated May 3, 2005
Reply to Non-Final Office Action of November 3, 2004
Page 7 of 13

fludarabin, gemcitabin and cytarabin, wherein the drug product comprises the customary pharmaceutical carriers, excipients and/or diluents in addition to the alkylphosphocholine of the Formula I and or II.

Claim 12 (amended): A drug product comprising at least one alkylphosphocholine of the general Formula I and or II as in claim 1 and, where appropriate, carriers and/or excipients for use in the treatment of benign and malignant oncoses before and/or during the treatment with an approved ~~antitumor medicament~~ antitumor substance chosen from cis-platinum, carboplatinum, oxaliplatinum, bleomycin, doxorubicin, methotrexate, paclitaxel, docetaxel, vincristine, vinblastine, etoposide, teniposide, ifosfamide, cyclophosphamide, 5-fluorouracil, fludarabin, gemcitabin and cytarabin.